Insilico Medicine announces US$888 million multi-year collaboration with Servier for drug discovery and development in oncology

Insilico Medicine and Servier have entered a multi-year research and development collaboration valued at up to US$888 million to discover and develop oncology therapies by combining Insilico’s AI-driven drug discovery platforms with Servier’s cancer drug development expertise.

Under the agreement, Insilico is eligible to receive up to US$32 million in upfront and near-term R&D payments and will apply its Pharma.AI platform and proprietary AI technologies to identify and advance potential drug candidates that meet predefined scientific and development criteria. Servier will share R&D costs and will lead clinical validation, regulatory interactions, and worldwide commercialization of any resulting drug candidates.

Insilico will lead the AI-driven discovery and early development work while Servier manages subsequent clinical and commercial activities. The companies expect the partnership to accelerate candidate selection and development timelines through tighter integration of generative AI and automation.

Christophe Thurieau, Executive Director Research at Servier, said the collaboration reflects the company’s commitment to applying advanced technologies to address unmet medical needs and its confidence in Insilico’s AI platform. Alex Zhavoronkov, founder and CEO of Insilico Medicine, said the agreement acknowledges the company’s AI capabilities and will deepen the use of generative AI across the pharmaceutical value chain.

Insilico currently has an oncology pipeline that includes the potential pan-TEAD inhibitor ISM6331 and the MAT2A inhibitor ISM3412, both in global, multicenter Phase I trials. Four other oncology programs have been fully or partially out-licensed to partners and are progressing through Phase I studies.

From 2021 to 2024 Insilico nominated 20 preclinical candidates, reporting an average timeline of 12 to 18 months from project initiation to preclinical candidate nomination and synthesizing and testing 60 to 200 molecules per program, compared with a typical early-stage discovery timeline of about 4.5 years.

Insilico Medicine is a clinical-stage biotechnology company that applies generative AI, deep learning and modern machine learning techniques to novel target discovery and molecular design across oncology, fibrosis, CNS, infectious, autoimmune and aging-related diseases. www.insilico.com